Generic Medicine Info
Indications and Dosage
Passive immunisation of infants against lower respiratory tract infections
Child: <2 yr 15 mg/kg mthly during the season of resp syncytial virus (RSV) risk. Subsequent doses should be given mthly until the end of the season. Undergone cardiac bypass surgery: 15 mg/kg as soon as stable post-op. Admin preferably in the anterolateral thigh; vol >1 mL should be given in divided doses.
Hypersensitivity to palivizumab or other humanised monoclonal antibodies.
Special Precautions
Patient w/ thrombocytopenia or other coagulation disorder, moderate to severe acute infection or febrile illness. Not intended for use in adult. Pregnancy and lactation.
Adverse Reactions
Fever, inj site reactions, nervousness, diarrhoea, vomiting, constipation, haemorrhage, rhinitis, cough, wheeze, pain, drowsiness, asthenia, hyperkinesia, leucopenia, rash, apnoea, convulsions, thrombocytopenia.
Potentially Fatal: Anaphylaxis and anaphylactic shock.
Lab Interference
May cause false-negative result w/ immunological-based RSV diagnostic test e.g. some antigen detection based assay.
Mechanism of Action: Palivizumab is a recombinant humanised monoclonal antibody which targets the surface glycoprotein, responsible for recognition and entry into the cell on the resp syncytial virus (RSV).
Absorption: Well absorbed. Bioavailability: 70%.
Excretion: Elimination half-life: 24.5 days.
Store between 2-8°C. Do not freeze.
MIMS Class
Vaccines, Antisera & Immunologicals
Anon. Palivizumab. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 06/11/2014.

Buckingham R (ed). Respiratory Syncytial Virus Immunoglobulins. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 06/11/2014.

Joint Formulary Committee. Palivizumab. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. Accessed 06/11/2014.

McEvoy GK, Snow EK, Miller J et al (eds). Palivizumab. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). Accessed 06/11/2014.

Synagis Injection, Solution (MedImmune, LLC). DailyMed. Source: U.S. National Library of Medicine. Accessed 06/11/2014.

Synagis Injection. U.S. FDA. Accessed 06/11/2014.

Disclaimer: This information is independently developed by MIMS based on Palivizumab from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in